Production (Stage)
Sarepta Therapeutics, Inc.
SRPT
$37.60
-$1.01-2.62%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -381.36% | 373.21% | 420.29% | -82.11% | -20.89% |
| Total Depreciation and Amortization | -4.56% | 6.62% | 12.47% | -0.29% | -23.11% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 185.83% | -53.63% | 127.08% | 5.79% | 10.53% |
| Change in Net Operating Assets | -125.43% | 42.30% | -377.37% | 86.23% | -119.32% |
| Cash from Operations | -733.85% | 230.19% | -573.16% | 106.17% | -342.90% |
| Capital Expenditure | -14.62% | -2.20% | -27.76% | 10.10% | -70.41% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -130.86% | 976.13% | -32.01% | -127.61% | 654.38% |
| Cash from Investing | -138.11% | 693.14% | -30.75% | -145.03% | 439.97% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -4,620.59% | -- | -- | -- | -- |
| Issuance of Common Stock | 322.67% | -73.03% | -65.54% | 80.30% | 1,039.48% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -74.54% | 256.12% | -65.54% | 80.30% | 1,039.48% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -195.25% | 587.25% | -325.41% | -3,730.53% | 99.03% |